Merck ends trial of potential Alzheimer’s drug verubecestatBMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j845 (Published 15 February 2017) Cite this as: BMJ 2017;356:j845
- Nigel Hawkes
The drug giant Merck has pulled the plug on a trial of an Alzheimer’s drug, verubecestat, after early data showed “virtually no chance” that it would work. But a second trial of the same drug continues in patients at an earlier stage of the disease.
Verubecestat was seen as a promising candidate in a field littered with failures, after data published last November showed that the drug reduced the levels of amyloid protein in the spinal fluid of patients and healthy controls who took it for …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial